T he novel interleukin IL23 was identified as recently as 2000. 1 IL23 is a heterodimer cytokine composed of a p40 subunit (shared with IL12) and the unique p19 subunit encoded by the IL23 gene. Recent genetic findings have confirmed previous immunological data that have implicated the IL23/IL17 pathway in inflammatory bowel disease (IBD) pathogenesis. In 2006, a number of studies identified the pivotal role of IL23 in driving intestinal inflammation via inflammatory mediators such as IL17. 2 The IL23 receptor (IL23R) is expressed on activated myeloid and T cells and IL23 is essential for maintaining the Th17 response. 3 IL17, the pivotal Th17 cytokine, is found at increased levels in IBD, 4 and in a model of bacteria-induced T-cell-dependent colitis, IL23 was implicated in driving both IFN␥ and IL17, thereby suggesting that IL23 plays a pivotal role in the development of mucosal inflammation. 2 Further evidence of the key role of IL23 in mucosal inflammation was provided in 2006 when an association between genetic variants in the IL23 receptor (IL23R) gene and IBD in Caucasians was identified by the North American IBD Genetics Consortium in a genome-wide association study (GWAS). 5 Importantly, this association with Crohn's disease (CD) has been widely replicated in diverse Caucasian populations. 6 -10 The original association with a single nonsynonymous single nucleotide polymorphism (SNP) has been supplemented with the finding that variants within the gene have a much greater contribution to disease susceptibility when haplotype-based analyses are performed. 11 A recently published meta-analysis of three CD GWASs not only confirmed the original association with IL23R, but also identified that genetic variants within IL12B, a downstream member of the IL23 pathway, are also implicated in CD pathogenesis, further highlighting the contribution of this pathway to the development of disease. 12 These data suggest that it would be worthwhile to further examine genes within the IL23/IL17 pathway in CD susceptibility. CD is a genetically complex disease where there are gene/environmental interactions and possibly gene/gene interactions (epistasis). There is increasing evidence from other genetically complex diseases, such as schizophrenia, that investigation of extended pathways known to contain susceptibility genes may reveal novel susceptibility variants. 13 The aim of this study was to examine the role of genes in the IL23/Th17 pathway in CD susceptibility and to investigate any evidence of epistasic interaction between these genes.
MATERIALS AND METHODS

Subjects
Following informed consent and approval by the Cedars-Sinai Medical Center Institutional Review Board, subjects were recruited at the Cedars-Sinai Medical Center Inflammatory Bowel Disease center. Diagnosis of CD was confirmed using a combination of standard endoscopic, histological, and radiographic features. 14 Controls were mainly spouses and acquaintances of CD subjects, and there was no difference in mean age between CD subjects and controls. In keeping with our previously published work, Ashkenazi Jewish ethnicity was assigned when at least 1 grandparent was of Ashkenazi Jewish origin. 15, 16 
Selection of Candidate Genes and SNPs
Genes were included for investigation if they were known to play a role in the IL23/IL17 pathway. 17 Specifically, the following 10 genes were chosen : IL12B, IL17A,  IL17RA, IL17RC, IL17RD, IL17F, IL17C, IL17D,  IL12RB1 , and IL12RB2. Data from previous investigation of IL23R were also available from a prior study. 11 SNPs were selected using "Tagger" 18 and data from the International HapMap Project. 19, 20 SNPs that "tagged" major Caucasian haplotypes and that were compatible with Illumina technology were genotyped. Since we were interested in major genetic effects rather than rare alleles, the goal of "tagging" was to find a set of tagSNPs in linkage disequilibrium with all SNPs in the HapMap data with a minor allele frequency Ն5%; in some cases this goal was not completely met due to the limitations of the Illumina technology. We also included nonsynonymous SNPs with a minor allele frequency greater than 3% and, when available, additional markers listed on the SeattleSNPs website (http://pga.mbt.washington.edu/welcome.html). This redundancy was added to compensate for marker failure in the large-scale genotyping.
Genotyping
DNA was isolated from Epstein-Barr virus-transformed lymphoblastoid cell lines using proteinase K digestion, organic extraction, and ethanol precipitation. 21 Single nucleotide markers (SNPs) were genotyped using the oligonucleotide ligation assay, Illumina Golden Gate technology 22 (Illumina, San Diego, CA). Details of all SNPs studied are given in Table 1 .
Statistical Analyses
HAPLOVIEW was used to determine the structure of haplotype blocks and to test for association between haplotypes and CD. 23 The association with CD and the presence of a haplotype was tested using the chi-square test, with estimation of the odds ratio (OR) and the 95% confidence interval (CI) for the haplotype effect. In order to assess the impact of multiple testing on the results, corrected P-values were calculated by performing 1000 random permutations of disease status for each tested haplotype and the proportion of permuted tests for which the value of the chi-square statistic was greater than for the actual or observed test. Results with significance were defined by P Ͻ 0.05 by permutation test. Individual haplotypes were reconstructed using PHASE (v.2) by assigning each haplotype with maximum probability. 24 Sixtyseven percent of haplotype assignments had probabilities of 100% and 98.5% had probabilities greater than 90%.
Mantel-Haenszel and logistic regression methods were used to determine the interaction between haplotypes in different genes. 25 In these analyses the results reported are for Jewish and non-Jewish subjects combined due to the fact that in the majority of cases there were no significant differences between Jewish and non-Jewish subjects ( Table 1) . The exceptions to this were: 1) that an IL17A "risk" haplotype specific to the non-Jewish population was identified and used for subsequent gene-gene interaction studies; and 2) that an IL12RB2 haplotype was observed specific to the Ashkenazi Jewish population and is reported below. Population attributable risk (PAR) or prevented fraction (PF) was estimated by assuming: 1) the frequency of a particular haplotype in the controls reflected the population frequency of that haplotype; and 2) the OR for the association of a given haplotype reflected the relative risk of that haplotype for CD. 26, 27 Thus, PAR ϭ P hap (OR-1)/[P hap (OR-1)ϩ1], when OR Ͼ1, or PF ϭ P hap (1-OR), when OR Ͻ1, where P hap ϭ frequency of a risk or preventive haplotype in the control group.
Haplotypes with frequency Ն5% are numbered in order of frequency (H1, H2, and so on). Gene-gene interactions were tested by using an interaction test in logistic regression models. 28 
RESULTS
We genotyped 763 CD subjects and 254 controls for SNPs in IL12B, IL17A, IL17RA, IL17RC, IL17RD, IL17F, IL17C, IL17D, IL12RB1, and IL12RB2 (for a full list of SNPs please see Table 1 and Suppl. Table 1 ). In addition to the associations demonstrated here with CD and genetic variation within the IL23/IL17 pathway, we have previously published an association between this CD cohort and haplotypes within 
Inflamm Bowel Dis Genetic Epistasis of IL23/IL17 Pathway Genes the gene encoding the IL23 receptor (IL23R) 11 (it is important to stress that these IL23R results are included in this article not as independent replication of this locus but in order to perform the "pathway" analyses and to assess for gene-gene interaction). These previous analyses suggested that IL23R
variants make a substantial contribution to CD susceptibility, with a PAR of Ϸ20%. 11 We found no association between CD and genetic variation in IL17RC (6 SNPs), IL17F (6 SNPs), IL17C (1 SNP), and IL17D (4 SNPs) (Suppl. We found both risk and protective CD associated haplotypes in IL17A, IL17RA, IL17RD, IL12B, IL12RB1, and IL12RB2 and CD (Table 1 ). In addition, there was a borderline association between an individual IL17RD SNP (rs768713, OR 0.80 (95% CI 0.65-0.98) and CD, an association that did not contribute to any of the haplotypes listed in Table 1 .
The IL17A haplotypes demonstrate that ethnic differences such as the H2 haplotype (rs2275913, rs3819025, rs10484879, rs1974226) is a protective haplotype in Ashkenazi Jewish CD (OR 0.51; 95% CI 0.28 -0.92), whereas it is a risk haplotype in the non-Jewish CD (OR 1.54; 95% CI 1.12-2.26). There is an analogous but converse finding in IL12RB2, where the protective H4 (rs1495964, rs1908632, rs11209063) haplotypic effect is seen in Ashkenazi Jews but not in non-Jewish cases ( Table 1) .
The cumulative risk of carrying an increased number of risk haplotypes from IL23R, IL17A, IL17RA, IL12RB1, and IL17RD in this cohort demonstrates an additive risk for CD as the number of risk haplotypes increases (Fig. 1) . Assuming an OR of 1 for carriage of no-risk haplotypes, the risk increases to an OR of 4.3 for carriage of 5 risk haplotypes. While limited power means that the individual analyses CIs are wide and cross 1, the proportion trend test for this analyses reveals a highly significant result with a P-value ϭ 1.7 ϫ 10 Ϫ7 (Fig.  1) .
Further evidence of the synergistic effect of the genes in this pathway in the development of CD can be seen in Table 2a -c and Figure 2 when the haplotypes are analyzed in pairs. These data should be contrasted with the association of Il23/IL17 pathway haplotypes with CD when analyzed individually (Table 1 ). In non-Jewish patients with CD, a significant increase in CD risk is seen for an IL23R risk haplotype, Block 2 Haplotype 1, or Block 3 Haplotype 1, only when the risk haplotype for IL17A, Haplotype 2 is also present (Table   2a , P for Mantel-Haenszel test ϭ 0.0017). A formal statistical interaction between these 2 risk haplotypes is significant, despite the modest size of sample available for this analysis (Table 2a , P for interaction ϭ 0.047). By a similar analysis, a significant increase in CD risk is seen for an IL23R risk haplotype only when the IL17RA risk haplotype is also present (Table 2b , P for Mantel-Haenszel test ϭ 0.0003, P interaction also significant at P ϭ 0.036). In addition, a significant decrease in CD risk is seen for an IL23R protective haplotype, Block 2 Haplotype 2, or Block 3 Haplotype 3, only when the protective haplotype of IL12RB2, haplotype 4, is also present (Table 2c , P for Mantel-Haenszel Ͻ 0.0001). A significant statistical interaction between these 2 protective haplotypes was also observed (P interaction ϭ 0.001). These data suggest that the widely replicated IL23R risk associations with CD may be limited to individuals who also "carry" other genetic variants within the IL17/IL23R pathway.
DISCUSSION
Previously published data using this cohort of subjects have demonstrated that for CD there are both "risk" and "protective" haplotypes in IL23R. 11 These haplotypic analyses substantially increase the estimate of the PAR for the IL23R gene to the order of Ϸ20% and reinforce the importance of IL23R in CD susceptibility. The significant genetic associations and high PARs reported in this article support the hypothesis that, in addition to IL23R, other genes in the IL17-IL23 pathway are major contributors to CD susceptibility. In addition to IL23R, associations were also observed between CD and common haplotypes in IL17A, IL17RA, IL17RD, IL12B, IL12RB1, and IL12RB2 (Table 2) . A "risk" haplotype, conferring a greater susceptibility to CD, and a "protective" haplotype, conferring a reduced susceptibility to CD, were observed with IL17A and with IL17RA, with a PAR for each of the order of Ϸ10%, and a "risk" haplotype was observed with IL12RB1 (PAR Ϸ40%). Furthermore, "risk" haplotypes of IL23R and IL17A and of IL23R and IL17RA synergistically interacted to increase CD risk ( Table 2, Fig.  2 ). The analysis herein using logistic regression modeling suggested that the increased risk for IL23R SNPs observed previously and for IL23R "risk" haplotypes in this report required the presence of additional "risk" haplotypes from IL17A or IL17RA. We have also demonstrated that specific haplotypes in genes can have differing effects on disease susceptibility in different ethnic groups, as an IL17A haplotype (H2) appears to be a risk haplotype in the non-Jewish subjects and a protective haplotype in the Jewish subjects. These findings substantiate similar findings that we have published in the TNFSF15 gene 29 and emphasize the need for appropriate accounting of ethnicity within genetic studies.
Further support for the importance of the IL17-IL23 pathway-related variants in CD susceptibility was the observation of an increasing OR for CD as the "risk" haplotypes . For haplotype assignments, see Table 1 .
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Genetic Epistasis of IL23/IL17 Pathway Genes for these genes were combined. While the OR for each "risk" haplotype alone is modest, on the order of 1.4 -1.6, the combined OR for the identified haplotypes is substantial, being greater than 4 ( Fig. 1) .
A limitation of this analysis is the relatively limited power as the number of subjects in the subgroups becomes modest with the increase in the number of risk and protective haplotypes to be analyzed in combination. The main observation of this study, namely, that genes in the IL23-IL17 pathway contribute to genetic susceptibility for CD, is robust and is supported by data from the GWAS meta-analysis 12 ; however, many of the details on interactions and the calculations of PARs should be considered provisional estimates or hypotheses at this time until confirmation in other cohorts of subjects have been reported. The impact of the number of haplotypes studied on the "multiple testing problem," that positive results may appear by chance and not by the presence of a true association was considered for the analyses of this study by comparing the significance of results with Ϸ1000 random permutations of the CD phenotype with the haplotype assignments.
The technological advances that have facilitated highthroughput and cost-effective genotyping and the increased understanding of the genetic structure of the human genome through the HapMap project have greatly accelerated genefinding for non-Mendelian/complex genetic traits. However, it is becomingly increasingly clear that identifying individual genes is only the first step in unraveling the genetic contribution to diseases such as CD. The observations in this study suggest that further genetic analysis of the pathway related to the original "hit" may uncover still more genetic variants that contribute substantially to susceptibility for the particular phenotype under study. The data also suggest that more complex analyses of related genes may need to be performed if subtle genetic interactions are to be revealed. These types of analyses may also reveal hitherto unknown genetic associations that only "reveal" themselves in these types of analyses. In summary, we have identified novel genetic variants within the IL23/IL17 pathway that contribute to CD susceptibility. Further work to consolidate these findings in other populations and to elucidate the "functional" consequences for the IL23/IL17 pathway of these genetic variants are warranted. Pairwise analysis demonstrate association between IL23R block 2 HI or block 3 H1 and IL17A (P ϭ 0.047 for interaction) (a) and IL17RA (P ϭ 0.036 for interaction) (b) haplotypes demonstrating that risk haplotypes from both genes are required for disease susceptibility.
